Ligufalimab

DB17542InvestigationalProtein Based Therapies

Ligufalimab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47. It is under investigation in clinical trial NCT04900350 (A Trial of AK117 (Anti-cd47) in Patients With...

Mechanism: Pharmacologically active on Leukocyte surface antigen CD47
Curator reviewed
Also known as: Immunoglobulin g4 (225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal ak117 .gamma.4-chain), disulfide with human-mus musculus monoclonal ak117 .kappa.-chain, dimer
Code names: AK 117

Resolves to

Compound

UNII1S4338NZB8CAS2428381-55-7

Targets

Q08722CD47

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

18Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ligufalimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account